Skip to main content
. Author manuscript; available in PMC: 2014 Oct 1.
Published in final edited form as: Surg Oncol Clin N Am. 2013 Jul 24;22(4):805–821. doi: 10.1016/j.soc.2013.06.001

Table 3.

New targeted agents under investigation for GIST.

Tyrosine kinase inhibitors Molecular Target Development phase
Nilotinib KIT, PDGFR, BCR-ABL110–112 Phase III
Dasatinib KIT, ABL, SRC113 Phase III
Sorafenib KIT, PDGFR, VEGFR, BRAF114–116 Phase II
Regorafenib KIT, PDGFRA, VEGFR, BRAF, FLT-3, Raf-174,117 Phase III
Masitinib KIT, PDGFR, LYN71,118 Phase III
Pazopanib KIT, PDGFRA, VEGFR Phase II
Vatalanib KIT, PDGFRA, VEGFR73,119 Phase II
Crenolanib PDGFRA D842V120 Phase II